A molecular scissor related to Alzheimer's disease
October 4, 2012 in Alzheimer's disease & dementia
The enzyme meprin is located at the cell wall (lined-up white balls). The enzyme binds a protein (red) within its active site cleft (light blue) to cleave it. Credit: Christoph Becker-Pauly & Xavier Gomis-Rüth
An international research team led by the Spanish National Research Council (CSIC) and researchers from Kiel University revealed the atomic‐level structure of the human peptidase enzyme meprin β (beta). The study was published online in the journal Proceedings of the National Academy of Sciences.
"Now that we know how meprin β looks, how it works and how it relates to diseases, we can search for substances that stop its enzyme activities when they become harmful", explains Xavier Gomis‐Rüth, researcher at the Molecular Biology Institute of Barcelona who led the project. Meprin β is an enzyme that is anchored in the outer wall of cells. Its normal function in the human metabolism is to cut off certain proteins, e.g. growth factors that are also anchored in the cell wall. In this way meprin β releases protein fragments into the environment surrounding the cells – a natural and normal process, as long as it occurs at certain intensity. However, under specific circumstances, meprin β may function abnormally, and for example, releases too many protein fragments. The protein pieces than overdo their natural task in the cell surroundings, causing disorder in the human body. Such disorder typically occurs when inflammation, cancer or Alzheimer's Disease get started.
In their study, the scientists found out that meprin βconsists of two identical molecules building a dimeric structure with a cleft in the middle. "We also discovered that the active site cleft is something like the scissor of the enzyme, the actual place where the proteins are cleaved", explains Christoph Becker-Pauly, researcher at the Institute of Biochemistry at Kiel University and principle investigator of the Collaborative Research Center 877 "Proteolysis as a Regulatory Event in Pathophysiology". Molecular biologist Gomes-Rüth points out to the next research goal: "We now need to find a substance that fits right into the cleft and will thus block the cleaving activity of meprin β." Such a substance could be the key to new therapeutical drugs against inflammation, cancer or Alzheimer's disease.
The research has been carried out in collaboration with scientists from Max Planck Institute for Biochemistry and Johannes Gutenberg University Mainz (Germany) as well as University of Bern (Switzerland).
Scientific background
Scientifically, meprin β belongs to the group of metalloproteases. "Meprin β is unique amongst all extracellular proteolytic enzymes, regarding its structure and cleavage specificity. With the help of proteomic techniques, we were recently able to identify the amyloid precursor protein (APP) as a substrate. It became obvious that meprin β is capable of releasing Aβ peptides, the main source of the typical amyloid plaques in Alzheimer brains, which is thought to be an initial step in the progression of Alzheimer's Disease.", adds Becker-Pauly.
He continues: "To solve the structure of the human enzyme in collaboration with Xavier Gomis-Rüth, we used insect cells, which yielded in high amounts of the recombinant protein and enabled the complex folding of meprin β. The structure does not only help to understand the molecular mechanism responsible for APP cleavage, but will also be employed to design highly specific and potent inhibitors, which might turn out as possible drugs for the treatment of neurodegenerative disorders or other diseases."
Journal reference:
Proceedings of the National Academy of Sciences
Provided by Spanish National Research Council
-
Enzyme involved in inflammatory bowel disease discovered
Jun 02, 2009 |
not rated yet |
0
-
Road block as a new strategy for the treatment of Alzheimer's
Aug 22, 2011 |
not rated yet |
0
-
New approach to Alzheimer's therapy
Jul 30, 2010 |
not rated yet |
0
-
'Alzheimer protein' seems to slow down neurotransmitter production
Aug 21, 2012 |
not rated yet |
0
-
Alzheimer's prevention role discovered for prions
Jul 03, 2007 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
The Durability of Bone: Long Falls
2 hours ago
-
Is energy convertible to matter?
4 hours ago
-
Rotating electron as a dipole is this right?
6 hours ago
-
Dipole term in multipole expansion
10 hours ago
-
Bubbles in a Pre-Boiling/Boiling pot of water
11 hours ago
-
Assumptions of Griffith's fracture theory
22 hours ago
- More from Physics Forums - Classical Physics
More news stories
Drugs found to both prevent and treat Alzheimer's disease in mice
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
Alzheimer's disease & dementia
10 hours ago |
5 / 5 (4) |
0
|
Scientists identify molecular trigger for Alzheimer's disease
Researchers have pinpointed a catalytic trigger for the onset of Alzheimer's disease – when the fundamental structure of a protein molecule changes to cause a chain reaction that leads to the death of neurons ...
Alzheimer's disease & dementia
May 20, 2013 |
5 / 5 (4) |
0
|
Study finds that sleep apnea and Alzheimer's are linked
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
Alzheimer's disease & dementia
May 19, 2013 |
5 / 5 (3) |
0
|
Alzheimer's leaves bilingual victims stranded in Canada
The devastating effect of Alzheimer's disease on bilingual people has been thrown into focus in Canada, where the sudden loss of a second language can leave sufferers feeling like strangers in their own country.
Alzheimer's disease & dementia
May 19, 2013 |
not rated yet |
0
Study identifies new approach to improving treatment for MS and other conditions
(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...
Alzheimer's disease & dementia
May 17, 2013 |
5 / 5 (2) |
0
|
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
Antidepressant reduces stress-induced heart condition
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.